Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Bernd Bokemeyer, Tibor Hlavaty, Matthieu Allez, Pamela Selema, Shahrzad Moosavi, Mary Jane Cadatal, Heather Fowler, Markus Mueller, Katherine F Liau & Javier P Gisbert. (2023) Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD). Expert Opinion on Biological Therapy 23:8, pages 791-800.
Read now
Read now
Ahmad Albshesh & Shomron Ben-Horin. (2019) CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel disease. Expert Opinion on Biological Therapy 19:10, pages 971-978.
Read now
Read now
Mercedes Gimeno-Gracia, Carla J. Gargallo-Puyuelo & Fernando Gomollón. (2019) Bioequivalence studies with anti-TNF biosimilars. Expert Opinion on Biological Therapy 19:10, pages 1031-1043.
Read now
Read now
Articles from other publishers (17)
Emilio Monte-Boquet, Ángeles Florez, Guillermo José Alcaín Martínez & Agustí Sellas. (2023) Documento de consenso sobre los medicamentos biosimilares en enfermedades inmunomediadas en España. Reumatología Clínica.
Crossref
Crossref
Valeria Dipasquale, Giuseppe Cicala, Edoardo Spina & Claudio Romano. (2022) Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence. Frontiers in Pharmacology 13.
Crossref
Crossref
Jérôme Avouac, Rodolphe Cougnaud Murail, Claire Goulvestre, Sophie Dumas, Anna Molto, Corinne Miceli-Richard, Ornella Conort, Frederic Batteux & Yannick Allanore. (2022) Immunogenicity of Rituximab biosimilar GP2013 in chronic inflammatory rheumatic disorders in daily clinical practice. Seminars in Arthritis and Rheumatism 52, pages 151951.
Crossref
Crossref
Amie Hinshaw, Kristen Cares, Ron Thomas & Mohammad El-Baba. (2022) Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator. JPGN Reports 3:4, pages e256.
Crossref
Crossref
Corrado Campochiaro, Alessandro Tomelleri, Silvia Sartorelli, Camilla Sembenini, Maurizio Papa, Federico Fallanca, Maria Picchio, Giulio Cavalli, Francesco De Cobelli, Elena Baldissera & Lorenzo Dagna. (2021) A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM). Frontiers in Medicine 8.
Crossref
Crossref
Rene Westhovens, Piotr Wiland, Marek Zawadzki, Delina Ivanova, Alfredo Berrocal Kasay, Elias Chalouhi El-Khouri, Éva Balázs, Sergii Shevchuk, Larisa Eliseeva, Mykola Stanislavchuk, Roman Yatsyshyn, Paweł Hrycaj, Janusz Jaworski, Vyacheslav Zhdan, Jakub Trefler, Pavel Shesternya, Sang Joon Lee, Sung Hyun Kim, Jee Hye Suh, Seul Gi Lee, Noo Ri Han & Dae Hyun Yoo. (2021) Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial. Rheumatology 60:5, pages 2277-2287.
Crossref
Crossref
Noopur Kumar, Turid Follestad, H. Nida Sen & Dordi Austeng. (2021) A Systematic Switch From Originator Infliximab to Biosimilar Infliximab in Patients With Non-Infectious Uveitis. American Journal of Ophthalmology 225, pages 178-184.
Crossref
Crossref
Guozhi Wu, Yuan Yang, Min Liu, Yuping Wang & Qinghong Guo. (2021) Systematic Review and Network Meta-Analysis: Comparative Efficacy and Safety of Biosimilars, Biologics and JAK1 Inhibitors for Active Crohn Disease. Frontiers in Pharmacology 12.
Crossref
Crossref
Mirko Di Ruscio, Angela Variola, Filippo Vernia, Gianluigi Lunardi, Paola Castelli, Paolo Bocus & Andrea Geccherle. (2021) Role of Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Subscore (MES) in Predicting Patients′ Response to Biological Therapy and the Need for Colectomy. Digestion 102:4, pages 534-545.
Crossref
Crossref
Ambre Lauret, Anna Moltó, Vered Abitbol, Loriane Gutermann, Ornella Conort, François Chast, Claire Goulvestre, Claire Le Jeunne, Stanislas Chaussade, Christian Roux, Frédéric Batteux, Maxime Dougados, Yannick Allanore & Jérôme Avouac. (2020) Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice. Seminars in Arthritis and Rheumatism 50:6, pages 1449-1456.
Crossref
Crossref
HoUng Kim, Rieke Alten, Luisa Avedano, Axel Dignass, Fernando Gomollón, Kay Greveson, Jonas Halfvarson, Peter M. Irving, Jørgen Jahnsen, Péter L. Lakatos, JongHyuk Lee, Souzi Makri, Ben Parker, Laurent Peyrin-Biroulet, Stefan Schreiber, Steven Simoens, Rene Westhovens, Silvio Danese & Ji Hoon Jeong. (2020) The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs 80:2, pages 99-113.
Crossref
Crossref
Daniel C. Baumgart, Laurent Misery, Sue Naeyaert & Peter C. Taylor. (2019) Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?. Frontiers in Pharmacology 10.
Crossref
Crossref
Akiko Ishii-Watabe & Takashi Kuwabara. (2019) Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies. Drug Metabolism and Pharmacokinetics 34:1, pages 64-70.
Crossref
Crossref
Alexandre Jentzer, Anne-Emmanuelle Berger, Rémi Labetoulle, Alice Haccourt, Xavier RoblinStephane Paul. (2018) Evaluation of Infliximab and Anti-infliximab LISA-TRACKER Immunoassays for the Therapeutic Drug Monitoring of SB2 Infliximab Biosimilar. Therapeutic Drug Monitoring 40:6, pages 749-753.
Crossref
Crossref
A. Mayoral-Zavala, A. Esquivel-Aguilar, C.M. del Real-Calzada, Y. Gutiérrez-Grobe, J. Ramos-García, J.L. Rocha-Ramírez, M.F. Rojas-Illanes, B. Rubio-Martínez, X. Sánchez-Chávez & J.K. Yamamoto-Furusho. (2018) Update on biosimilars in inflammatory bowel disease: Position and recommendations in Mexico. Revista de Gastroenterología de México (English Edition) 83:4, pages 414-423.
Crossref
Crossref
A. Mayoral-Zavala, A. Esquivel-Aguilar, C.M. del Real-Calzada, Y. Gutiérrez-Grobe, J. Ramos-García, J.L. Rocha-Ramírez, M.F. Rojas-Illanes, B. Rubio-Martínez, X. Sánchez-Chávez & J.K. Yamamoto-Furusho. (2018) Actualización sobre los medicamentos biocomparables en la enfermedad inflamatoria intestinal: posición y recomendación en México. Revista de Gastroenterología de México 83:4, pages 414-423.
Crossref
Crossref
Don Husereau, Brian Feagan & Carl Selya-Hammer. (2018) Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching. Applied Health Economics and Health Policy 16:3, pages 279-288.
Crossref
Crossref